US-based Veniti has received US Food and Drug Administration (FDA) approval for an investigational device exemption (IDE) to initiate the virtus trial of the Veniti VICI venous stent system.

The company said that the Veniti VICI venous stent system was designed to be compatible with the unique anatomy and pathophysiology of the venous system.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The only treatment options available to treat lower-extremity venous disease involved the use of re-purposed vascular stents originally designed for use in the arterial system.

"The development of stents specifically designed for the unique characteristics of the venous system provide the potential to reduce these debilitating symptoms for patients."

Co-principal investigator of the Virtus trial William Marston said: "Obstruction of the iliac veins and vena cava have been identified as a frequent cause of severe venous disease resulting in major disabling symptoms including leg swelling, pain, and ulceration.

"The development of stents specifically designed for the unique characteristics of the venous system provide the potential to reduce these debilitating symptoms for patients, while improving the cost-effectiveness of interventional treatment for venous obstruction."

See Also:

St Joseph Hospital’s Heart and Vascular Center clinical trials and research director Mahmood Razavi said: "Due to the absence of vein-specific stents, physicians have thus far been using stents that were not designed for veins.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We look forward to the completion of this important study and availability of optimal stents to treat our patients with deep vein obstructive lesions."

The trial has started in Europe, with first patients enrolled and treated at Hospital Madrid Monteprincipe in Madrid, Spain.

Veniti president and chief executive officer Scott Solano said: "The unique advantages of a stent designed specifically for the venous system, including end-to-end crush resistance, flexibility, and continuous vein coverage, may offer significant patient benefit."